141 related articles for article (PubMed ID: 32979020)
1. Non-selective beta-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD ≥ 12 over 5 years of follow-up.
Calès P; Bertrais S; Boursier J; Fouchard I; Oberti F;
Liver Int; 2021 Jan; 41(1):168-179. PubMed ID: 32979020
[TBL] [Abstract][Full Text] [Related]
2. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.
Scheiner B; Parada-Rodriguez D; Bucsics T; Schwabl P; Mandorfer M; Pfisterer N; Riedl F; Sieghart W; Ferlitsch A; Trauner M; Peck-Radosavljevic M; Reiberger T
Scand J Gastroenterol; 2017 Sep; 52(9):1008-1015. PubMed ID: 28532189
[TBL] [Abstract][Full Text] [Related]
3. Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites.
Onali S; Kalafateli M; Majumdar A; Westbrook R; O'Beirne J; Leandro G; Patch D; Tsochatzis EA
Liver Int; 2017 Sep; 37(9):1334-1344. PubMed ID: 28296047
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices.
Paternostro R; Becker J; Hofer BS; Panagl V; Schiffke H; Simbrunner B; Semmler G; Schwabl P; Scheiner B; Bucsics T; Bauer D; Binter T; Trauner M; Mandorfer M; Reiberger T
Dig Liver Dis; 2022 Apr; 54(4):500-508. PubMed ID: 34799282
[TBL] [Abstract][Full Text] [Related]
5. Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation.
Ngwa T; Orman E; Gomez EV; Vuppalanchi R; Kubal C; Chalasani N; Ghabril M
BMC Gastroenterol; 2020 Jan; 20(1):4. PubMed ID: 31906860
[TBL] [Abstract][Full Text] [Related]
6. The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis.
Sersté T; Njimi H; Degré D; Deltenre P; Schreiber J; Lepida A; Trépo E; Gustot T; Moreno C
Liver Int; 2015 Aug; 35(8):1974-82. PubMed ID: 25611961
[TBL] [Abstract][Full Text] [Related]
7. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers.
Shukla R; Kramer J; Cao Y; Ying J; Tansel A; Walder A; Advani S; El-Serag HB; Kanwal F
Am J Gastroenterol; 2016 Dec; 111(12):1778-1787. PubMed ID: 27670600
[TBL] [Abstract][Full Text] [Related]
8. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding.
Pfisterer N; Dexheimer C; Fuchs EM; Bucsics T; Schwabl P; Mandorfer M; Gessl I; Sandrieser L; Baumann L; Riedl F; Scheiner B; Pachofszky T; Dolak W; Schrutka-Kölbl C; Ferlitsch A; Schöniger-Hekele M; Peck-Radosavljevic M; Trauner M; Madl C; Reiberger T
Aliment Pharmacol Ther; 2018 Apr; 47(7):966-979. PubMed ID: 29388229
[TBL] [Abstract][Full Text] [Related]
9. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.
Bossen L; Krag A; Vilstrup H; Watson H; Jepsen P
Hepatology; 2016 Jun; 63(6):1968-76. PubMed ID: 26599983
[TBL] [Abstract][Full Text] [Related]
10. Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?
Kim TW; Kim HJ; Chon CU; Won HS; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
Clin Mol Hepatol; 2012 Jun; 18(2):203-12. PubMed ID: 22893871
[TBL] [Abstract][Full Text] [Related]
11. Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States.
Wijarnpreecha K; Li F; Xiang Y; Xu X; Zhu C; Maroufy V; Wang Q; Tao W; Dang Y; Pham HA; Zhou Y; Li J; Zhang X; Xu H; Taner CB; Yang L; Tao C
Aliment Pharmacol Ther; 2021 Aug; 54(4):481-492. PubMed ID: 34224163
[TBL] [Abstract][Full Text] [Related]
12. Effect of Nonselective β-Blockers on Mortality in Patients With End-Stage Cirrhosis.
Snoga JL; Lusk KA; Attridge RT; Attridge RL
Ann Pharmacother; 2020 Apr; 54(4):322-330. PubMed ID: 31701773
[No Abstract] [Full Text] [Related]
13. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study.
Kang SH; Lee M; Kim MY; Lee JH; Jun BG; Kim TS; Choi DH; Suk KT; Kim YD; Cheon GJ; Kim DJ; Baik SK
Hepatol Int; 2021 Apr; 15(2):424-436. PubMed ID: 33860898
[TBL] [Abstract][Full Text] [Related]
14. Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis.
Labenz C; Nagel M; Toenges G; Kuchen R; Schattenberg JM; Hilscher M; Huber Y; Marquardt JU; Labenz J; Galle PR; Wörns MA
Eur J Intern Med; 2020 Dec; 82():83-89. PubMed ID: 32873457
[TBL] [Abstract][Full Text] [Related]
15. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.
Mookerjee RP; Pavesi M; Thomsen KL; Mehta G; Macnaughtan J; Bendtsen F; Coenraad M; Sperl J; Gines P; Moreau R; Arroyo V; Jalan R;
J Hepatol; 2016 Mar; 64(3):574-82. PubMed ID: 26519600
[TBL] [Abstract][Full Text] [Related]
16. Immune changes over time and survival in patients with cirrhosis treated with non-selective beta-blockers: A prospective longitudinal study.
Almenara S; Lozano-Ruiz B; Herrera I; Gimenez P; Miralles C; Bellot P; Rodriguez M; Palazon JM; Tarín F; Sarmiento H; Francés R; Gonzalez-Navajas JM; Pascual S; Zapater P
Biomed Pharmacother; 2023 Jul; 163():114885. PubMed ID: 37201262
[TBL] [Abstract][Full Text] [Related]
17. Non-selective beta-blocker use in cirrhotic patients is associated with a reduced likelihood of hospitalisation for infection.
Sasso R; Rockey DC
Aliment Pharmacol Ther; 2021 Feb; 53(3):418-425. PubMed ID: 33314175
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of acute variceal bleeding: Is being on beta-blockers an aggravating factor? A short-term survival analysis.
de Souza AR; La Mura V; Berzigotti A; García-Pagán JC; Abraldes JG; Bosch J
Hepatology; 2015 Dec; 62(6):1840-6. PubMed ID: 26340692
[TBL] [Abstract][Full Text] [Related]
19. The 35-year odyssey of beta blockers in cirrhosis: any gender difference in sight?
Burza MA; Marschall HU; Napoleone L; Molinaro A
Pharmacol Res; 2017 May; 119():20-26. PubMed ID: 28099882
[TBL] [Abstract][Full Text] [Related]
20. Nonselective beta-blockers may lead to stage 2 acute kidney injury and waitlist mortality in child class C cirrhosis.
Lai M; Fenton C; Ge J; Rubin J; Lai JC; Cullaro G
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37756037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
